269 related articles for article (PubMed ID: 9031099)
21. Homologous recombinational repair vis-à-vis chlorambucil resistance in chronic lymphocytic leukemia.
Bello VE; Aloyz RS; Christodoulopoulos G; Panasci LC
Biochem Pharmacol; 2002 May; 63(9):1585-8. PubMed ID: 12007561
[TBL] [Abstract][Full Text] [Related]
22. Comparison of infrared spectra of CLL cells with their ex vivo sensitivity (MTT assay) to chlorambucil and cladribine.
Liu KZ; Schultz CP; Johnston JB; Lee K; Mantsch HH
Leuk Res; 1997; 21(11-12):1125-33. PubMed ID: 9444947
[TBL] [Abstract][Full Text] [Related]
23. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
24. Nitrogen mustard drug resistant B-cell chronic lymphocytic leukemia as an in vivo model for crosslinking agent resistance.
Bramson J; McQuillan A; Aubin R; Alaoui-Jamali M; Batist G; Christodoulopoulos G; Panasci LC
Mutat Res; 1995 May; 336(3):269-78. PubMed ID: 7739615
[TBL] [Abstract][Full Text] [Related]
25. Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.
Panovská A; Němcová L; Nekvindová L; Špaček M; Šimkovič M; Papajík T; Brejcha M; Lysák D; Zuchnická J; Novák J; Starostka D; Poul H; Vrbacký F; Vodárek P; Urbanová R; Plevová K; Pospíšilová Š; Mašlejová S; Brychtová Y; Koriťáková E; Smolej L; Doubek M
Hematol Oncol; 2020 Oct; 38(4):509-516. PubMed ID: 32400885
[TBL] [Abstract][Full Text] [Related]
26. Relationship between nitrogen mustard drug resistance in B-cell chronic lymphocytic leukemia (B-CLL) and protein expression of Bcl-2, Bax, Bcl-X and p53.
Christodoulopoulos G; Fotouhi N; Krajewski S; Reed JC; Alaoui-Jamali M; Panasci L
Cancer Lett; 1997 Dec; 121(1):59-67. PubMed ID: 9459175
[TBL] [Abstract][Full Text] [Related]
27. The Impact of Chlorambucil and Valproic Acid on Cell Viability, Apoptosis and Expression of
Lipska K; Filip A; Gumieniczek A
Cells; 2021 May; 10(5):. PubMed ID: 34063233
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of resistance to chlorambucil in chronic lymphocytic leukemia.
Begleiter A; Goldenberg GJ; Anhalt CD; Lee K; Mowat MR; Israels LG; Johnston JB
Leuk Res; 1991; 15(11):1019-27. PubMed ID: 1961006
[TBL] [Abstract][Full Text] [Related]
29. Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies.
Lepretre S; Dartigeas C; Feugier P; Marty M; Salles G
Leuk Lymphoma; 2016; 57(4):852-65. PubMed ID: 26308278
[TBL] [Abstract][Full Text] [Related]
30. Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia.
Johnston JB; Paul JT; Neufeld NJ; Haney N; Kropp DM; Hu X; Cheang M; Gibson SB
Leuk Lymphoma; 2004 Oct; 45(10):2017-27. PubMed ID: 15370246
[TBL] [Abstract][Full Text] [Related]
31. In vitro improvement of chlorambucil-induced cytotoxicity by deflazacort and 6-methylprednisolone in B-cell chronic lymphocytic leukaemia.
Morabito F; Callea I; Irrera G; Cartisano G; Dattola A; Rodinò A; Brugiatelli M
Eur J Haematol; 1997 May; 58(5):301-6. PubMed ID: 9222284
[TBL] [Abstract][Full Text] [Related]
32. Modulation of purine analogs- and chlorambucil-induced cytotoxicity by alpha-interferon and interleukin-2 in chronic lymphocytic leukemia.
Morabito F; Callea I; Rodinò A; Messina G; Callea V; Iacopino P; Nobile F; Brugiatelli M
Leukemia; 1995 Sep; 9(9):1450-5. PubMed ID: 7658711
[TBL] [Abstract][Full Text] [Related]
33. Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) - a systematic review and meta-analysis of randomized trials.
Vidal L; Gurion R; Ram R; Raanani P; Bairey O; Robak T; Gafter-Gvili A; Shpilberg O
Leuk Lymphoma; 2016 Sep; 57(9):2047-57. PubMed ID: 26980554
[TBL] [Abstract][Full Text] [Related]
34. [Effect of chlorambucil on B-lymphocytes in the peripheral blood of patients with chronic lymphocytic leukemia--study of cellular ultrastructure].
Brajusković G; Marjanović S; Skaro-Milić A
Vojnosanit Pregl; 2003; 60(2):175-80. PubMed ID: 12852160
[TBL] [Abstract][Full Text] [Related]
35. Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.
Liso V; Molica S; Capalbo S; Pogliani E; Battista C; Broccia G; Montillo M; Cuneo A; Leoni P; Specchia G; Castoldi G
Haematologica; 2001 Nov; 86(11):1165-71. PubMed ID: 11694402
[TBL] [Abstract][Full Text] [Related]
36. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia.
Dighiero G; Maloum K; Desablens B; Cazin B; Navarro M; Leblay R; Leporrier M; Jaubert J; Lepeu G; Dreyfus B; Binet JL; Travade P
N Engl J Med; 1998 May; 338(21):1506-14. PubMed ID: 9593789
[TBL] [Abstract][Full Text] [Related]
37. A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia.
Städler N; Shang A; Bosch F; Briggs A; Goede V; Berthier A; Renaudin C; Leblond V
Adv Ther; 2016 Oct; 33(10):1814-1830. PubMed ID: 27535291
[TBL] [Abstract][Full Text] [Related]
38. Chlorambucil plus theophylline vs chlorambucil alone as a front line therapy for B-cell chronic lymphatic leukemia.
Mabed M; Aref S; Fouda M; El-Sharawy S
Leuk Lymphoma; 2004 Oct; 45(10):2029-35. PubMed ID: 15370247
[TBL] [Abstract][Full Text] [Related]
39. A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.
Hebb J; Assouline S; Rousseau C; Desjardins P; Caplan S; Egorin MJ; Amrein L; Aloyz R; Panasci L
Cancer Chemother Pharmacol; 2011 Sep; 68(3):643-51. PubMed ID: 21120481
[TBL] [Abstract][Full Text] [Related]
40. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
Roué G; López-Guerra M; Milpied P; Pérez-Galán P; Villamor N; Montserrat E; Campo E; Colomer D
Clin Cancer Res; 2008 Nov; 14(21):6907-15. PubMed ID: 18980985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
